HIGHLIGHTS
- who: Riham M. Karkeet and colleagues from the Cairo University, Cairo, Egypt, Virology and Immunology Unit, Cancer Biology Department, National have published the Article: The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial, in the Journal: PLOS ONE of October/24,/2022
- what: This study has been initiated to investigate, on mechanism-based, the possible therapeutic effects of rosuvastatin when combined with androgen deprivation in metastatic prostate cancer patients. Of this study demonstrated that LDL, TG and TC were significantly lower after 6 month . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.